By attenuating LysoPCs (18:1, 20:2, P-18:0, O-18:0)-induced inflammation, CRP helped stabilize hepatocyte membranes, mitigate liver injury, and slow NAFLD progression. Here, CRP is linked to metabolic dysfunction-associated steatotic liver disease.